Evidence map›Paper›PMID 33574248›Full record

ReviewNature communications2021

Renal metabolism and hypertension.

Zhongmin Tian, Mingyu Liang

Open access · goldAbstract readReview
In one paragraph

Review in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it, 141 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Renal gluconeogenesis: a key metabolic hub in health and kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Human plasma metabolomics reveals metabolic targets for intervention in salt-sensitive hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Zhongmin TianThe Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, China.ORCID http://orcid.org/0000-0002-6414-6354
Mingyu LiangCenter of Systems Molecular Medicine, Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA. mliang@mcw.edu.ORCID http://orcid.org/0000-0002-6970-989X
Medical College of Wisconsin · USXi'an Jiaotong University · CN

Funding

Therapeutic Effects of mTOR Inhibition in Salt-Sensitive HypertensionP01HL116264 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI MATTSON, DAVID L. · 2013 to 2021
$18.7M
Regulatory RNA in Hypertension and Renal InjuryR01HL121233 · NHLBI · UNIVERSITY OF ARIZONA · PI MINGYU LIANG · 2014 to 2026
$3.8M
NHLBI NIH HHS P01 HL116264NHLBI NIH HHS R01 HL121233
6 · The paper itself

Abstract

Hypertension is a leading risk factor for disease burden worldwide. The kidneys, which have a high specific metabolic rate, play an essential role in the long-term regulation of arterial blood pressure. In this review, we discuss the emerging role of renal metabolism in the development of hypertension. Renal energy and substrate metabolism is characterized by several important and, in some cases, unique features. Recent advances suggest that alterations of renal metabolism may result from genetic abnormalities or serve initially as a physiological response to environmental stressors to support tubular transport, which may ultimately affect regulatory pathways and lead to unfavorable cellular and pathophysiological consequences that contribute to the development of hypertension.

Indexed as

AnimalsHumansHypertensionKidneyKidney DiseasesMitochondriaNephronsRisk Factors

Identifiers

PMID33574248
PMCPMC7878744
OpenAlexW3128649693

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.